(Q37837059)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

review article

1 reference

title

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Mark D. Gorrell

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Johannes B. Prins

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

C F Deacon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

Internal Medicine Journal

21 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

299-307

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21299778%20AND%20SRC:MED&resulttype=core&format=json

Ernest Starling and the discovery of secretin

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

The incretin concept today

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Hamster preproglucagon contains the sequence of glucagon and two related peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

What do we know about the secretion and degradation of incretin hormones?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Caveolin-1 regulates cellular trafficking and function of the glucagon-like Peptide 1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

The dipeptidyl peptidase IV family in cancer and cell biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Beta cell mass in diabetes: a realistic therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Potential of liraglutide in the treatment of patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2011.02439.X